ArticleJournal of hepatocellular carcinoma2026
Preoperative Prediction of Glypican-3 Expression in Hepatocellular Carcinoma Using Sonazoid Contrast-Enhanced Ultrasound Radiomics.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate a noninvasive radiomics approach based on Sonazoid contrast-enhanced ultrasound (CEUS) for preoperative prediction of Glypican-3 (GPC3) status in solitary hepatocellular carcinoma (HCC) patients and to evaluate its association with early recurrence-free survival (RFS). Materials and Methods: This diagnostic accuracy study retrospectively included 278 solitary HCC patients at a grade A Tertiary Hospital (2020.3-2024.1). Radiomics features were extracted from CEUS images, and robust feature selection was performed using minimum redundancy-maximum relevance (mRMR) and least absolute shrinkage and selection operator (LASSO). A logistic-regression radiomics model was trained and internally validated using a pathologic reference standard. A hybrid model combining the radiomics signature with significant clinical variables was then constructed. Model performance was assessed by the area under the receiver operating characteristic curve (AUC). RFS was compared using the log‑rank test. Results: Among 278 patients (median age, 57 years; IQR, 49-64 years; 232 males), alpha-fetoprotein (AFP) > 200 ng/mL and the radiomics score were independent predictors of GPC3 positivity. The hybrid model integrating CEUS-based radiomics features and AFP achieved AUCs of 0.81 (95% CI: 0.74-0.89) and 0.78 (95% CI: 0.66-0.89) in the training and validation sets, respectively, significantly outperforming the radiomics model (AUC 0.74 (95% CI: 0.65-0.83) and 0.67 (95% CI: 0.52-0.83), both Conclusion: A hybrid model integrating CEUS-based radiomics features and AFP, developed in solitary HCC, shows potential for non-invasive preoperative prediction of GPC3 positive expression in HCC, which may facilitate personalized preoperative treatment planning for these patients. However, it did not predict early recurrence-free survival, and its prognostic value was not demonstrated in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.